Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIa : Therapy response monitoring in breast cancer, lymphoma and gliomas

Positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) is considered to be a very useful adjunct to anatomic imaging techniques and is now primarily used for oncological indications. These indications include diagnosis, staging, and therapy monitoring. In this review, we discuss the a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2001-05, Vol.127 (5), p.269-277
Main Authors: VAN DER HIEL, B, PAUWELS, E. K. J, STOKKEL, M. P. M
Format: Article
Language:English
Subjects:
Animals
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Breast Neoplasms - diagnostic imaging
Breast Neoplasms - therapy
Central Nervous System Neoplasms - diagnostic imaging
Central Nervous System Neoplasms - therapy
Evaluation Studies as Topic
Female
Fluorodeoxyglucose F18 - pharmacokinetics
General aspects
Glioma - diagnostic imaging
Glioma - therapy
Humans
Lymphoma - diagnostic imaging
Lymphoma - therapy
Male
Medical sciences
Neoplasm Metastasis - diagnostic imaging
Neoplasms - diagnostic imaging
Neoplasms - therapy
Outcome Assessment (Health Care) - methods
Pharmacology. Drug treatments
Rats
Tomography, Emission-Computed
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) is considered to be a very useful adjunct to anatomic imaging techniques and is now primarily used for oncological indications. These indications include diagnosis, staging, and therapy monitoring. In this review, we discuss the articles in which FDG-PET is clinically used for monitoring therapy in breast cancer, lymphomas and gliomas. It is found that the amount of FDG uptake strongly correlates with response to therapy in breast cancer, lymphomas, and gliomas; a decrease in FDG uptake after therapy indicates a positive response to therapy. However, this conclusion is based on small patient numbers, whereas the exact response mechanism is still unknown. Therefore, more studies in comparable patient groups are required to achieve a better understanding of FDG uptake patterns after therapy. Part IIIb deals with lung, and head and neck cancer, hepatocellular and colorectal tumours, and sarcoma.
ISSN:0171-5216
1432-1335
DOI:10.1007/s004320000191